Cramer, D.W., Fichorova, R.N., Terry, K.L., Yamamoto, H., Vitonis, A.F., Ardanaz, E., Aune, D., Boeing, H., Brändstedt, J., Boutron-Ruault, M.C., Chirlaque, M.D., Dorronsoro, M., Dossus, L., Duell, E.J., Gram, I.T., Gunter, M., Hansen, L., Idahl, A., Johnson, T., Khaw, K.T., Kaaks, R., et al. (2018) Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology, Biomarkers & Prevention, 27, 790-804.
https://doi.org/10.1158/1055-9965.EPI-17-0744

has been cited by the following article:

• TITLE: New Progress of CA125 Surveillance in Diagnosis and Treatment of Ovarian Cancer

  AUTHORS: Kaiwen Du, Junying Tang

  KEYWORDS: CA125, Epithelial Ovarian Cancer

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.5, May 11, 2024

  ABSTRACT: The fatality rate of ovarian cancer (OC) is the highest, and the 5-year survival rate is only 50.8%. For more than 40 years, CA125 has been the most concerned and widely used biomarker of OC in clinical practice. In recent years, many researchers have proposed a reliable strategy of multiple markers combined with CA125 to screen OC to make up for the lack of accuracy of CA125, redefine the biochemical recurrence threshold of CA125, and use mathematical model scores to provide help for the feasibility of treatment and survival prognosis. To fully understand the role of CA125 in OC screening, initial treatment, and recurrence prediction, and summarize the limitations of CA125, this review has summarized the new progress of CA125 in the diagnosis and treatment of OC in recent years which can also provide a reference for clinicians.